Surgery Partners, Inc. (NASDAQ:SGRY) announced it will release its fourth quarter 2025 earnings results on March 2, 2026, followed by a conference call on March 3, 2026 at 8:30 a.m. ET. The company, a leading short-stay surgical facility owner and operator with over 200 locations across 30 states, will provide investors with access to the call via phone and webcast.
Surgery Partners, Inc. Common Stock (SGRY)
Common Stock · Currency in USD · XNAS
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Company Info
SIC8062
Composite FIGIBBG009T0TKV8
CIK0001638833
IPOOct 1, 2015
Sectorservices-general medical & surgical hospitals, nec
Highlights
Market Cap$1.58B
EPS-$0.72
P/E Ratio15.58
Revenue$3.30B
Gross Profit$3.29B
Net Income$101.20M
Employees16,000
WSO129,419,836
Phone615-234-5900
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Surgery Partners, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Surgery Partners, Inc. Common Stock (SGRY) has returned -21.11% so far this year and -40.76% over the past 12 months. Looking at the last ten years, SGRY has achieved an annualized return of -0.50%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
SGRY
1M-12.25%
6M-42.52%
YTD-21.11%
1Y-40.76%
5Y-23.09%
10Y-0.50%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Surgery Partners, Inc. Common Stock (SGRY) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.76% | 4.31% | -22.70% | 2.18% | ||||||||
| 2025 | 18.06% | -5.53% | -4.08% | -7.58% | 7.56% | -5.44% | -1.26% | 4.47% | -3.61% | 1.76% | -21.84% | -9.12% |
| 2024 | -2.88% | 0.32% | -3.77% | -16.28% | 10.93% | -14.05% | 27.72% | 5.58% | 2.74% | -10.28% | -17.65% | -10.30% |
| 2023 | 16.41% | 0.84% | -1.51% | 14.23% | -5.57% | 19.97% | -13.37% | -3.59% | -19.73% | -20.71% | 42.27% | -1.72% |
| 2022 | -17.97% | 21.70% | 4.58% | -7.32% | -23.14% | -26.71% | 36.93% | -28.92% | -12.52% | 14.58% | 2.09% | -2.52% |
| 2021 | 26.59% | 4.22% | 10.46% | 10.23% | 19.79% | 11.91% | -17.98% | -10.14% | -14.65% | -3.68% | 8.12% | 17.02% |
| 2020 | 5.57% | -2.96% | -60.35% | 88.50% | 17.59% | -13.85% | 31.52% | 23.32% | 15.14% | -0.37% | 10.00% | 16.41% |
| 2019 | 35.40% | -4.35% | -11.25% | -4.92% | -21.16% | -5.35% | -8.29% | -15.49% | 16.12% | 7.72% | 71.82% | 13.44% |
| 2018 | 28.51% | 2.92% | 10.65% | -5.60% | 1.25% | -8.87% | 1.68% | 14.14% | -4.62% | -17.39% | 5.36% | -32.06% |
| 2017 | 15.26% | 21.29% | -14.29% | -11.79% | 26.38% | 4.60% | -13.13% | -51.25% | 6.15% | -11.48% | 25.33% | 28.04% |
| 2016 | 23.22% | -15.56% | 30.37% | 0.95% | 5.53% | 5.20% | -19.74% | -9.23% | 7.82% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Surgery Partners, Inc. Common Stock (SGRY) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of SGRY compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Surgery Partners, Inc. Common Stock volatility is 2.52%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 8.12B | 7.89B | 6.88B | 6.68B | 6.12B | 5.41B | 5.02B | 4.68B | 4.62B | 2.30B | 2.11B |
| Temporary Equity Attributable To Parent (USD) | - | - | - | - | - | 434.50M | 395.00M | 359.35M | 330.81M | - | - |
| Temporary Equity (USD) | 395.50M | 438.80M | 327.40M | 342.00M | 330.20M | 741.30M | 716.00M | 685.94M | 630.12M | 180.52M | 183.44M |
| Equity Attributable To Parent (USD) | 1.71B | 1.79B | 1.99B | 2.00B | 1.09B | 115.60M | 296.80M | 404.64M | 654.73M | 9.68M | -4.03M |
| Equity Attributable To Noncontrolling Interest (USD) | 1.42B | 1.41B | 1.05B | 942.70M | 880.60M | 766.50M | 686.60M | 694.31M | 681.88M | 315.00M | 301.96M |
| Equity (USD) | 3.13B | 3.20B | 3.03B | 2.94B | 1.97B | 882.10M | 983.40M | 1.10B | 1.34B | 324.67M | 297.93M |
| Redeemable Noncontrolling Interest (USD) | 395.50M | 438.80M | 327.40M | 342.00M | 330.20M | 306.80M | 321.00M | 326.59M | 299.32M | 180.52M | 183.44M |
| Other Non-current Liabilities (USD) | 637.50M | 664.60M | 515.40M | 613.70M | 652.90M | 1.10B | 1.04B | 899.89M | 796.87M | 319.04M | 341.46M |
| Long-term Debt (USD) | 3.74B | 3.40B | 2.80B | 2.63B | 2.96B | 2.88B | 2.60B | 2.33B | 2.19B | 1.47B | 1.29B |
| Noncurrent Liabilities (USD) | 4.37B | 4.07B | 3.32B | 3.25B | 3.61B | 3.97B | 3.64B | 3.23B | 2.98B | 1.79B | 1.63B |
| Other Current Liabilities (USD) | 341.90M | 355.30M | 277.40M | 272.90M | 334.80M | 391.20M | 247.20M | 210.80M | 168.67M | 107.69M | 109.67M |
| Wages (USD) | 64.90M | 60.40M | 73.80M | 68.90M | 77.10M | 65.40M | 54.20M | 55.21M | 49.63M | 29.27M | 26.31M |
| Accounts Payable (USD) | 208.70M | 208.70M | 171.80M | 151.60M | 124.90M | 100.20M | 96.70M | 83.29M | 84.71M | 49.77M | 45.34M |
| Current Liabilities (USD) | 615.50M | 624.40M | 523.00M | 493.40M | 536.80M | 556.80M | 398.10M | 349.30M | 303.01M | 186.73M | 181.31M |
| Liabilities (USD) | 4.99B | 4.69B | 3.84B | 3.74B | 4.15B | 4.53B | 4.04B | 3.58B | 3.29B | 1.98B | 1.81B |
| Other Non-current Assets (USD) | 6.93B | 6.72B | 5.93B | 5.72B | 5.13B | 4.56B | 4.45B | 4.03B | 4.00B | 1.89B | 1.74B |
| Intangible Assets (USD) | 41.00M | 45.70M | 54.80M | 42.30M | 43.70M | 46.90M | 47.30M | 54.29M | 58.91M | 48.02M | 53.57M |
| Noncurrent Assets (USD) | 6.97B | 6.77B | 5.98B | 5.76B | 5.17B | 4.61B | 4.49B | 4.09B | 4.06B | 1.94B | 1.80B |
| Other Current Assets (USD) | 1.01B | 994.60M | 788.80M | 818.20M | 859.40M | 727.50M | 461.40M | 528.73M | 501.44M | 322.02M | 277.96M |
| Prepaid Expenses (USD) | 41.10M | 36.40M | 31.00M | 31.40M | 25.60M | 17.60M | 17.80M | 16.23M | 16.84M | 11.16M | 7.41M |
| Inventory (USD) | 96.60M | 88.40M | 75.20M | 71.40M | 61.10M | 56.40M | 46.30M | 43.36M | 44.95M | 28.78M | 25.59M |
| Current Assets (USD) | 1.15B | 1.12B | 895.00M | 921.00M | 946.10M | 801.50M | 525.50M | 588.32M | 563.23M | 361.96M | 310.96M |
| Assets (USD) | 8.12B | 7.89B | 6.88B | 6.68B | 6.12B | 5.41B | 5.02B | 4.68B | 4.62B | 2.30B | 2.11B |
News and Insights
Irenic Capital Management sold 1,047,583 shares of Surgery Partners (SGRY) in Q4 2025, reducing its stake to just 0.09% of assets. The stock has declined 39.7% over the past year, underperforming the S&P 500 by 51.61 percentage points. While the company's operations remain solid with 6.6% revenue growth, concerns center on high leverage with net debt to EBITDA at 4.2x-4.6x in a higher rate environment.
The global ambulatory surgical center (ASC) market is projected to grow from US$ 85.9 billion in 2024 to US$ 142.6 billion by 2033, driven by cost-effectiveness, favorable reimbursement policies, expanding CMS-approved procedures, and patient preference for outpatient surgeries. Physician-owned ASCs dominate with 59.56% market share, while North America leads globally with 26.46% share. Key growth factors include significant cost savings compared to hospital outpatient departments and technological advancements enabling more complex procedures.
Surgery Partners priced $425 million in senior unsecured notes due 2032, intending to use proceeds for general corporate purposes including repaying outstanding borrowings under its revolving credit facility.
AirSculpt Technologies appointed Mike Doyle as Non-Executive Chairman of its Board of Directors. Doyle brings over 30 years of leadership experience in multi-center healthcare and has previously led Surgery Partners and founded MD Healthcare Partners.
Surgery Partners experienced a significant stock drop of nearly 25% after reporting Q3 earnings that missed analyst expectations, with lower-than-anticipated non-GAAP earnings and revenue, despite a 7% year-over-year revenue growth.
Surgery Partners will release its Q3 2025 financial results on November 10, 2025, before market opening, followed by a conference call at 8:30 a.m. Eastern Time.
Surgery Partners reported Q2 2025 revenue of $826.2 million, an 8.4% year-over-year increase, with mixed financial results. The company saw strong case volume growth and reaffirmed full-year guidance, despite challenges with net losses and higher network growth costs.
Surgery Partners will release its second quarter 2025 financial results on August 5, 2025, with a conference call at 8:30 a.m. Eastern Time, providing investors an opportunity to hear about the company's performance.
Surgery Partners, Inc. Confirms Receipt of Non-Binding Acquisition Proposal from Bain Capitalneutral
Surgery Partners, Inc. has received a non-binding acquisition proposal from Bain Capital to acquire all outstanding shares not already owned by Bain Capital for $25.75 per share. A special committee of independent directors will consider the proposal with the assistance of advisors.